Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2842 - Programmed death ligand-1overexpression is a poor prognostic factor for Human papillomavirus-positive tonsillar squamous cell carcinoma


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Head and Neck Cancers


Mi Jung Kwon


Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374


M.J. Kwon1, M. Hong2, S.Y. Kang3

Author affiliations

  • 1 Pathology, Hallym University Sacred Heart Hospital, 431-796 - anyang/KR
  • 2 Pathology, Kangnam Sacred Heart Hospital, 134-701 - seoul/KR
  • 3 Pathology, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR


Abstract 2842


Programmed death-ligand 1 (PD-L1) plays a key role for immune evasion, contributing to carcinogenesis and tumor progression. Tonsillar squamous cell carcinomas (TSCCs) are the most common human papillomavirus (HPV)-associated oropharyngeal cancers and they frequently present with locally advanced diseases and cervical metastases, which are associated with poor prognoses. Recent studies have reported the close association between PD-L1 and HPV in head and neck SCCs. However, its clinical and prognostic significances in TSCCs remain controversial.


Immunohistochemical analysis of PD-L1 was performed in 79 formalin-fixed paraffin-embedded blocks of surgically resected specimens. Peptide nucleic acid-based HPV chip test was used for detection of HPV.


PD-L1 expression was observed in 19 cases (24.1%), and clinicopathological features such as invasion to base of tongue, lymphatic invasion, infiltrative tumor border, younger age (


PD-L1 overexpression may predict a poor prognosis and a high risk of recurrence in TSCC patients, especially in HPV-positive tonsil cancers, implying PD-L1 could be potent candidates for a new prognostic and predictive biomarker in tonsil cancers.

Clinical trial identification

none of clinical trial

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.